Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain (MMSET) in Prostate Cancer Cells (Q38740526)

From Wikidata

Jump to navigation Jump to search

scientific article published on 12 July 2016

Language	Label	Description	Also known as
English	Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain (MMSET) in Prostate Cancer Cells	scientific article published on 12 July 2016

Statements

scholarly article

1 reference

Europe PubMed Central

6 September 2017

Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain (MMSET) in Prostate Cancer Cells (English)

1 reference

Europe PubMed Central

6 September 2017

1 reference

based on heuristic

inferred from title

multiple myeloma

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Nicole M A White-Al Habeeb

1

1 reference

Europe PubMed Central

6 September 2017

Julia Garcia

2

1 reference

Europe PubMed Central

6 September 2017

Neil Fleshner

3

1 reference

Europe PubMed Central

6 September 2017

Bharati Bapat

4

1 reference

Europe PubMed Central

6 September 2017

publication date

12 July 2016

1 reference

Europe PubMed Central

6 September 2017

1 reference

Europe PubMed Central

6 September 2017

76

1 reference

Europe PubMed Central

6 September 2017

1507-1518

1 reference

Europe PubMed Central

6 September 2017

16

1 reference

Europe PubMed Central

6 September 2017

The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Long-term metformin use is associated with decreased risk of breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Metformin and reduced risk of cancer in diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Diabetes therapy and cancer risk: causal effects and other plausible explanations

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Antidiabetic therapies affect risk of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Metformin: multi-faceted protection against cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Epigenetics in prostate cancer: biologic and clinical relevance

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

The epigenome as a therapeutic target in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Epigenetics of prostate cancer: beyond DNA methylation

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

EZH2, an epigenetic driver of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

CR Cistrome: a ChIP-Seq database for chromatin regulators and histone modification linkages in human and mouse

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Short-term treatment with metformin suppresses toll like receptors (TLRs) activity in isoproterenol-induced myocardial infarction in rat: are AMPK and TLRs connected?

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

In Vitro and In Vivo Modulation of Alternative Splicing by the Biguanide Metformin

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma: lack of concurrent activation of both proto-oncogenes.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23235

21 January 2018

Identifiers

10.1002/PROS.23235

1 reference

Europe PubMed Central

6 September 2017

1 reference

Europe PubMed Central

6 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38740526&oldid=1856206352"